Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

56.75 -0.27 (-0.47%)
Streaming Delayed Price Updated: 3:59 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
35 36 Next >
News headline image
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations ↗
Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S. 
Via Benzinga
News headline image
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen 
Via Benzinga
News headline image
Tesla's India Move, Adidas Receives Orders For Massive Unsold Yeezy Inventory, Spotify Raises Subscription Prices: Today's Top Stories ↗
Wall Street Journal 
Via Benzinga
News headline image
Why Novartis Stock Spiked Today ↗
A massive share buyback program and an improved outlook powered a mid-single-digit rise in the drugmaker's shares today. 
Via The Motley Fool
News headline image
Stock Analysis: Roche Holding AG ↗
Roche is a Swiss biopharmaceutical and diagnostic company. 
Via Talk Markets
News headline image
Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy ↗
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to  
Via Benzinga
News headline image
New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss
From Genentech
Via Business Wire
News headline image
Q2 Earnings Scorecard And Analyst Reports ↗
We now have Q2 results from 38 S&P 500 members. 
Via Talk Markets
News headline image
Nvidia Invested $50 million into This AI Drug Discovery Biotech
Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from 
Via MarketBeat
Topics Artificial Intelligence
News headline image
2 Nasdaq Stocks That Could Soar This Week ↗
BridgeBio Pharma and Roivant Sciences could make big moves this week. 
Via The Motley Fool
News headline image
Hollywood Wants To Use AI Replicas Of Actors, Major US Banks Deliver Q2 Earnings, Artificial Sweetener Aspartame Classified As 'Possible Carcinogen:' Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
Roivant Surges As Roche Reportedly Considers $7 Billion Drug Takeover ↗
The report sent Roivant Sciences higher Friday, but a deal is far from guaranteed. 
Via Investor's Business Daily
News headline image
Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal ↗
Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY) 
Via Benzinga
News headline image
How Roche Just Cut Top 1% Biotech Stock TG Therapeutics Down A Peg ↗
The companies are rivals in the multiple sclerosis treatment realm with Ocrevus and Briumvi. 
Via Investor's Business Daily
News headline image
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion ↗
Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with... 
Via Benzinga
News headline image
Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis
From Genentech
Via Business Wire
News headline image
Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal ​Muscular ​Atrophy (SMA)​ Able to Sit, Stand and Walk
From Genentech
Via Business Wire
News headline image
Monkeypox Vaccine: Blue Water Biotech Touts Encouraging Preclinical Data From Monkeypox Vaccine Candidate ↗
Blue Water Biotech Inc (NASDAQ: BWV) has released preliminary preclinical data that supports the potential use of its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform for the... 
Via Benzinga
News headline image
Agilent Technologies Stock: Ready to Rise off the Floor
Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider. 
Via MarketBeat
News headline image
Roche's Bispecific Antibody With Fixed-Duration Treatment Scores FDA Approval For Type Of Lymphoma ↗
The FDA approved Roche Holding AG's (OTC: RHHBY) Columvi (glofitamab-gxbm) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma (LBCL)... 
Via Benzinga
News headline image
FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
From Genentech
Via Business Wire
News headline image
EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035 ↗
JonesResearch has initiated coverage of ophthalmic biopharmaceutical company EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) with a Buy rating and  
Via Benzinga
News headline image
New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control ↗
Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies e 
Via Benzinga
News headline image
New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)
From Genentech
Via Business Wire
News headline image
Why Shares of Zentalis Pharmaceuticals Dropped This Week ↗
A rash of insider selling meant the stock gave back some of its gains from last week. 
Via The Motley Fool
News headline image
Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class ↗
Roche tested its treatment in patients with liver cancer and found "meaningful" results. 
Via Investor's Business Daily
News headline image
Why Shares of Rain Oncology Are Plummeting Today ↗
The company released disappointing top-line results for its lead oncology therapy. 
Via The Motley Fool
News headline image
Apple Thwarts $2B In Fraud Transactions, UBS Takes $17B Hit From 'Hasty Credit Suisse Takeover,' Verizon Streamlines Unlimited Data Plans: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows ↗
Roche Holdings AG's  (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS)  
Via Benzinga
News headline image
Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis
From Genentech
Via Business Wire
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.